GALDERMA GRP AG
182,40€
-1,45 (-0,79%)
25.08.2026, 11:31:47 Uhr
WKN: A407X6 ISIN: CH1335392721 Wertpapiertyp: Aktie Währung: Euro
- 1T
- 1W
- 1M
- 3M
- 6M
- 1J
- 3J
- 5J
- 10J
- Max
Weltmärkte
- DAX ® +195,31 +0,75% 26.301,91
- MDAX ® -78,86 -0,25% 32.031,55
- TecDAX ® -41,41 -1,01% 4.049,23
- E-STOXX 50 ® -14,24 -0,22% 6.447,98
- NASDAQ 100 -285,68 -0,97% 29.023,18
- HANG SENG -16,92 -0,07% 25.511,10
Kursperformance
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Tag | 183,85€ | -0,79% |
| 1 Woche | 179,65€ | +2,34% |
| 1 Monat | 186,00€ | -1,16% |
| 6 Monate | 156,65€ | +17,36% |
| Lfd. Jahr (YTD) | -- | -- |
| 1 Jahr | -- | -- |
| 3 Jahre | -- | -- |
| 5 Jahre | -- | -- |
Kursdaten
| Kurs | 182,40€ |
| Schluss Vortag | 183,85€ |
| Eröffnung | 183,65€ |
| Geld | 183,00€ |
| Brief | 183,10€ |
| Tages-Hoch | 183,95€ |
| Tages-Tief | 182,40€ |
| 52 Wochen-Hoch | 204,00€ |
| 52 Wochen-Tief | 149,00€ |
| Allzeit-Hoch | 204,00€ |
| Allzeit-Tief | 149,00€ |
Nachrichten
- BUSINESS WIRE: Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping - 11.08.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year - 23.07.2026, 07:00:02 Uhr
- BUSINESS WIRE: Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region - 20.07.2026, 07:00:03 Uhr
- BUSINESS WIRE: Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns - 07.07.2026, 07:00:06 Uhr
- BUSINESS WIRE: Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States - 01.07.2026, 07:00:07 Uhr
- BUSINESS WIRE: Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments - 11.06.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch - 22.05.2026, 18:25:04 Uhr
- BUSINESS WIRE: Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency - 23.04.2026, 07:00:03 Uhr
- BUSINESS WIRE: Galderma Shareholders Approve All Annual General Meeting Proposals - 22.04.2026, 17:45:02 Uhr
- BUSINESS WIRE: Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform - 16.04.2026, 07:00:02 Uhr
